Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Barr Laboratory BRL -- Ignore unavailable to you. Want to Upgrade?

To: Uncle Mikey who wrote (120)	8/24/1998 11:36:00 PM
From: harkenman	Read Replies (2) \| Respond to of 207

Value Line Assessment on BRL is BUY!!! Timeliness 2 (Raised from previous) Safety 4 Technical 3 (Lowered) Beta 0.75 Institutional Decisions 37 Buy; 12 Sell EPS June 30 $0.38 vs $0.35 Value Line estimate Trading at P/E of 21.8 vs 31.3 (Mylan) Sales per share 19.15 vs 5.80 (Mylan) Return capital 22 vs 15 (Mylan) Tax Rate 38% vs 31.5% (Mylan) Can improve on Tax rate ! Overall Company has stong fundamentals low following hence the lower technical rating. You can hype this stock but there is nothing to hype. Its only solid growth. Future is in Coumadin, Tamoxifen, Danazol. Proxac patent challenge etc.